<?xml version="1.0" encoding="UTF-8"?>
<p id="p0380">To succeed rapidly in the research and development (R&amp;D) of COVID-19, animal models that can mimic the human disease characteristics need to identify urgently to perform in-vivo preclinical studies. Therapeutics (anti-viral agents) and clinical trials of drugs for prophylactic use need to be developed to protect the risk population. To reduce the mortality and improve clinical disease outcome; the research agenda should cover the investigation of prophylaxis, combination therapies, evaluation and safety studies of repurposed agents to progress in the battle against COVID-19outbreak.</p>
